Toggle navigation
About Us
Business Areas
R & D
Manufacturing
Beyond Business
Investors
Careers
Contact Us
Investors
Investors > FY 2023-24
Overview
Chairman's Statement
Shareholder Information
Policies or Statutory Documents
IEPF
Debentures
Amalgamation
MOA/AOA
Procedure for Dematerialisation of Shares
Archives
Credit Ratings
CSR
AGM Transcript
Annual Return
Disclosures under Regulation 46 and 62 of SEBI LODR
Financial
2024-25
2023-24
2022-23
2021-22
2020-21
2019-20
2018-19
2017-18
2016-17
2015-16
2014-15
2013-14
2012-13
2011-12
Investors > FY 2023-24
1. Annual Report
Annual Report 2023-24 (Single page view)
Annual Report 2023-24
Torrent Pharma Inc
Torrent Do Brasil Ltda
Heumann Pharma GmbH & Co
Heunet Pharma GmbH
Torrent Pharma GmbH
Torrent Pharma Philippines Inc
Zao Torrent Pharma
Torrent Pharma (UK) Ltd
Laboratorios Torrent, S.A. de C.V
Laboratories Torrent Malaysia Sdn. Bhd
Torrent Pharma (Thailand) Co.Ltd
Torrent Australasia Pty. Ltd
Torrent Pharma (Malta) Limited
TPL (Malta) Ltd
Curatio Inc.
Torrent International Lanka (Pvt) Limited (Formerly known as Curatio International Lanka (Private) Limited)
Farmaceutica Torrent Colombia SAS
2. Intimation to Stock Exchange
Disclosure pursuant to Regulation 30 read with Schedule III and Regulation 33 of SEBI(Listing Obligations and Disclosure Requirements), 2015, ("Listing Regulations")
Compliance as per Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation of Record Date for the purpose of payment of final dividend for the year 2023-24
Intimation for Presentation to analysts on Audited Financial Results for the quarter and year ended 31st March, 2024
Disclosure pursuant to Regulation 30 read with Schedule III and Regulation 33 of SEBI - BM Outcome
Secretarial Compliance Report for the year ended 31st March, 2024
Shareholding Pattern Q4
Intimation for Trading Window Closure_Q4
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Change in Senior Management Personnel (SMP)
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Transcript of Conference call with Analysts / Investors on Financial Results for Q3 2023-24
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Submission / Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) – BM 02-02-2024
Intimation for Presentation to analysts on financial Results for the quarter and nine months ended 31st December, 2023
Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation for Concall with Investors/Analyst Q3_2023-24
Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Shareholding Pattern Q3
Intimation of Board Meeting dated 02-02-2024
Intimation of Record Date_Interim Dividend
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation for Incorporation of Wholly Owned Subsidiary (WOS)
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation for Trading Window Closure_Q3
Partial Redemption of Non-Convertible Debentures issued under ISIN: INE685A07082
Payment of Interest & Partial Redemption of Non-Convertible Debentures issued under ISIN: INE685A07082
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation of Credit Rating
Transcript of Conference call with Analysts / Investors on Financial Results for Q2 2023-24
Compliance as per Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation for Presentation to analysts on financial Results for the quarter ended 30th September, 2023
Intimation for Concall with Investors/Analyst Q2_2023-24
Shareholding Pattern Q2
Intimation of the board meeting dated 23-10-2023
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Change in Senior Management Personnel (SMP)
Intimation for Trading Window Closure_Q2
Intimation of Credit Rating
Press Release – Torrent Pharmaceuticals gets EIR from US FDA for Dahej facility
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Transcript of Conference call with Analysts / Investors on Financial Results for the quarter ended 30th June, 2023
Newspaper Advertisement Results Q1
Voting Results & Scrutinizer’s Report AGM dated 07-08-2023
Appointment of Nikhil Khattau as an Independent Director of the Company
Alteration of Articles of Association of the Company
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Proceedings of 50th Annual General Meeting of the Company held on 07th August, 2023
Intimation for Presentation to analysts on financial Results for the quarter ended 30th June, 2023
Shareholding Pattern Q1
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation for Concall with Investors / Analyst Q1_2023-24
Intimation of the Board Meeting dated 07-08-2023
Newspaper advertisement in respect of Annual General Meeting and E-Voting Procedure
Newspaper advertisement regarding Intimation of the 50th AGM of the Company through VC/OAVM facility
Intimation for Trading Window Closure_Q1
USFDA Pre-Approval Inspection of Oral Oncology Manufacturing facility, Gujarat
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI Listing Regulations_ Final NCLT Order wrt scheme of amalgamation of Curatio Health Care (I) Private Limited with Company
Intimation for Concall with Investors / Analyst Q4_2022-23
Intimation of the Board Meeting dated 30-05-2023
Redemption of Non-Convertible Debentures issued under ISIN:INE685A07108
Redemption of Non-Convertible Debentures issued under ISIN:INE685A07116
3. Postal Ballot & E-voting
Postal Ballot Result and Scrutinizer’s Report – 27th November, 2023
Stock Exchange Intimation - Newspaper advertisement for completion of dispatch of Postal Ballot Notice 2023
Stock Exchange Intimation Postal Ballot Notice 2023
Postal Ballot Notice 2023
4. Quarterly Results
Q1 23-24
Q2 23-24
Q3 23-24
Q4 23-24
Newspaper Advertisement Q1
Q1FY24 Earnings Call Transcript
Press Release
Standalone Result
Consolidated Results
Audio Recording of conference call on Financial Results for the quarter ended June 30, 2023
Newspaper Advertisement Results Q2
Q2FY24 Earnings Call Transcript
Audio Recording of conference call on Financial Results for the quarter and half year ended September 30, 2023
Press Release
Standalone Result
Consolidated Results
Q3FY24 Earnings Call Transcript
Newspaper Advertisement Results Q3
Audio Recording of conference call on Financial Results for the quarter and nine months ended December 31, 2023
Press Release
Standalone Results
Consolidated Results
Q4FY24 Earnings Call Transcript
Newspaper Advertisement Results Q4
Audio Recording of conference call on Financial Results for the quarter and year ended March 31, 2024
Consolidated Results
Standalone Results
Press Release
5. Shareholder Communication Tax on Dividend
Shareholder’s Communication – Tax on Final Dividend
Shareholder’s Communication – Tax on Interim Dividend
Details of Nodal Officer
Name
: Chintan Trivedi
Designation
: Company Secretary
E-mail Id
: investorservices@torrentpharma.com
IEPF Authority - Refund web page
IEPF Authority - Refund web page >>